Lung adenocarcinomas harboring oncogenic driver mutations at the level of EGFR and ROS1 and ALK rearrangements have a lower mutational load, often occur in never smokers and are sensitive to targeting with specific inhibitors and this offered new therapeutic perspectives for these patients. Here, ROS1 is linked to lung adenocarcinoma.